OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Weiss Discusses Current Clinical Trials in Head and Neck Cancer

July 19th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses current clinical trials in head and neck cancer.

Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

July 19th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

Dr. Sankhala on Challenges Facing the Treatment of Angiosarcoma

July 19th 2017

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

July 19th 2017

Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

July 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Dr. Cohen Discusses Immunotherapy Combinations in Head and Neck Cancer

July 18th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Dr. Hurria on Treatment Options for the Geriatric Population with Breast Cancer

July 17th 2017

Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, discusses treatment for the geriatric patient population with breast cancer.

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast Cancer

July 17th 2017

Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer

July 15th 2017

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Dr. Brufsky on the Disease-Free Survival of Aromatase Inhibitors for Breast Cancer

July 15th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the 5 versus 10 year disease-free survival of aromatase inhibitors investigated in the NSAPB B-42 trial.

Dr. Hendifar on the Current Treatment Landscape in Pancreas Cancer

July 14th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the current treatment landscape in pancreas cancer.

Dr. Matasar on Antibody-Drug Conjugates in B-Cell Malignancies

July 14th 2017

Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates in B-cell malignancies.

Dr. Bekaii-Saab on the Potential Impact of Napabucasin Combo in Pancreatic Cancer

July 13th 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Dr. Lenz Discusses Targeted Combinations in Colorectal Cancer

July 13th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses combinations with targeted agents in colorectal cancer.

Dr. Klein on Precision Medicine for Prostate Cancer

July 13th 2017

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

July 13th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer

July 13th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer

July 13th 2017

Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

Dr. Voorhees on Pivotal Ongoing Trials in Multiple Myeloma

July 12th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

July 12th 2017

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).